Vectura Group plc

home / authors / vectura-group-plc

Articles

Executive Summary: Leveraging the Evolving Bioequivalence Regulatory Landscape to Enhance Inhaled Product Design and Development

Vectura Group plc;Vectura

February 28th 2025

The regulatory landscape for bioequivalence continues to evolve, leveraging a broader suite of characterization techniques. These not only provide deeper product understanding, but also utility for generic product development as the potential for replacement of costly clinical studies becomes more of a reality.

Control Strategies and Method Development for Nitrosamines in APIs and Drug Products

Biologic therapies: Charting the path from injectables to inhalation

Vectura Group plc

November 5th 2024

Webinar Date/Time: Thu, Nov 14, 2024 11:00 AM EST

Leveraging the Evolving Bioequivalence Regulatory Landscape to Enhance Product Design & Development

Vectura Group plc

July 10th 2024

Webinar Date/Time: Tue, Jul 30, 2024 11:00 AM EDT

Vectura – Helping You Succeed with Inhaled Product Development

Vectura Group plc

September 22nd 2020

Vectura helps customers bring inhaled medicines to market with a combination of formulation science, device technology, and inhaled product development expertise.

Dry Powder Inhalers: Key Considerations for Combination Product Development

Vectura Group plc

June 24th 2020

Dry powder inhalers (DPIs) are an important delivery technology for inhaled medicines in both respiratory and non-respiratory disease areas. Andreas Meliniotis, director of device development at Vectura, helps navigate the complex area of DPI product development and highlights the key considerations for both novel- and generic-drug programs. Live: Wednesday, Jun. 24, 2020 at 11am EDT |8am PDT |4pm BST |5pm CEST On demand available after final airing Jun. 24, 2021 Register free